合伙人
Jin Ooi律师专注于重大知识产权争议及战略咨询,尤其在专利诉讼领域拥有丰富经验。他代理的案件涉及广泛的技术领域,包括制药与生命科学、电信及消费品等。其业务涵盖专利诉讼、标准必要专利(SEP)及公平、合理和无歧视(FRAND)许可争议、商业秘密纠纷、复杂损害赔偿评估以及监管事务,并经常涉及多个司法辖区的平行诉讼及相关程序。Jin律师曾代理多起由英国专利法院、上诉法院及最高法院审理的案件。《IAM Patent 1000》等权威法律评级机构称其为“极为出色的专利专家”,并特别赞誉其“卓越的判断力和洞察力”。
Jin律师尤其以其在生命科学领域专利诉讼方面的经验而广受认可。他所处理的事项涵盖制药、生物技术、医疗器械及其他前沿技术,包括小分子药物、生物制剂及生物类似药、DNA测序、疫苗、用于抗体发现的转基因动物平台、人工耳蜗以及经导管心脏瓣膜等。凭借法律和药理学的双重专业背景,Jin 能够从科学、法律、监管及商业等多个维度,就创新产品全生命周期所涉及的复杂问题为客户提供综合性建议。Jin律师曾代理大型制药公司处理围绕重磅药物展开的具有里程碑意义的专利争议,并在申请临时禁令、应对仿制药企业针对专利有效性发起的协同挑战,以及复杂损害赔偿评估程序等方面积累了丰富经验。其中包括一起受到业界广泛关注的后续损害赔偿案件,该案涉及医药专利诉讼中因临时禁令申请方作出的交叉赔偿承诺而产生的损害赔偿问题。
除生命科学领域外,Jin律师在科技领域专利争议方面亦拥有深厚经验。他曾参与多起英国具有代表性的标准必要专利及FRAND争议,包括涉及临时许可声明及全球许可的复杂案件。此外,他还代理过围绕非燃烧型减害消费产品展开的重大长期专利争议。凭借横跨多个技术领域的广泛经验,《JUVE Patent》将其誉为“全能型律师”,指出其“所处理案件的技术领域高度多元,从制药、移动通信到电子烟均有涉及,同时以勤奋和坚韧著称”。
Jin律师代理的许多案件涉及具有重要战略意义的跨境知识产权争议,需要在多个司法辖区之间进行统筹协调。他经常与欧洲及其他重要市场的律师团队密切合作,为客户制定全球协调一致的诉讼策略。《IAM》评价其“善于协调复杂的多司法辖区专利争议”,并指出他“能够娴熟统筹不同国家的诉讼策略,确保各地法律团队协调一致,并针对不同司法辖区的特定挑战灵活调整应对方案”。
除专利诉讼外,Jin律师还拥有丰富的商业秘密纠纷经验,涉及医疗器械、航空航天、航空及重工业等领域。他亦经常处理知识产权与商事诉讼相交叉的复杂事项,包括合同及监管争议。此外,Jin律师在生命科学监管咨询及相关交易业务方面亦具备丰富经验,包括为受监管行业的并购交易提供支持。
Jin律师获得《Chambers UK》《The Legal 500 UK》《IAM Patent 1000》《JUVE Patent》《Managing Intellectual Property (MIP)》等多家权威法律评级机构的认可。业内评价其为实力卓著的领军人物,并赞誉其拥有“卓越的法律洞察力”和“敏锐把握关键法律问题的能力”。客户尤其认可其“出色的诉讼代理能力”“始终如一的快速响应”以及“对细节极为缜密而专业的把控”,并高度评价其在技术高度复杂的争议中制定有效诉讼策略的能力。一位客户近期评价道:“Jin真正有别于市场上其他律师之处,在于他能够将复杂的法律问题提炼为清晰、切实可行的建议,即使在时间压力极大的情况下亦能如此。”
Dr Reddy’s Laboratories (UK) Limited v. Boehringer Ingelheim International GmbH*
Successfully represented Boehringer Ingelheim to obtain interim injunction relief against Dr Reddy’s on patents covering the blockbuster medicine Jardiance® (empagliflozin) for treating type 2 diabetes mellitus, heart failure, and chronic kidney disease. This matter was named one of the “Top 20 Cases of 2026” by The Lawyer.
[2025] EWHC 2834 (Pat), Claim number: HP-2024-000037, Patents Court
Successfully represented Astellas Pharma and The Regents of the University of California in defeating validity challenges brought by multiple generic companies on patents covering the blockbuster medicine Xtandi® (enzalutamide) for treating prostate cancer. This matter was named a 2026 “Europe Cross-border Patent Litigation Team of the Year” at Managing IP’s EMEA Awards.
[2024] EWHC 2524 (Pat), Claim numbers: HP-2022-000030, HP-2023-000002, and HP-2023-000011, Patents Court
[2025] EWCA Civ 936, Appeal numbers: CA-2024-002655/002675/002676, Court of Appeal
Assisted leading multinational consumer electronics corporations in successfully obtaining interim licence declarations in high-profile standard essential patent (SEP) disputes. These matters were parts of actions before English courts, seeking the determination of global Fair, Reasonable, and Non-Discriminatory (FRAND) terms for licences and cross-licences covering the parties’ mobile phone technology SEP portfolios.
[2024] EWCA Civ 1143, Appeal number: CA-2024-001709, Patents Court
[2025] EWCA Civ 182, Appeal number: CA-2024-002821, Court of Appeal
[2025] EWHC 1432 (Pat), Claim number: HP-2024-000044, Patents Court
Dr Reddy’s Laboratories (UK) Limited & Ors v. Warner-Lambert Company LLC & Anor*
Represented Pfizer and Warner-Lambert in the “most complex follow-on damages inquiry ever heard before the Patents Court” against the Department of Health, NHS bodies and numerous generic companies arising from cross-undertakings in damages given during the pendency of substantive patent proceedings covering the blockbuster medicine Lyrica® (pregabalin) for treating neuropathic pain. This matter was named one of the “Top 20 Cases of 2023” by The Lawyer.
[2020] EWHC 628 (Pat), Claim number: HP-2015-000007, Patents Court
[2021] EWHC 2182 (Ch), Claim numbers: HP-2015-000007, HC-2014-001795, HP-2014-000021, HP-2015-000049, HP-2015-000006, HP-2020-000031, HP-2020-000032, HP-2020-000033 and HP-2020-000038, Patents Court
[2022] EWHC 189 (Pat), Claim numbers: HP-2015-000007, HC-2014-001795, HP-2014-000021, HP-2015-000049 and HP-2020-000034, Patents Court
[2022] EWHC 1856 (Ch), Claim numbers: HP-2015-000007, HC-2014-001795, HP-2014-000021, HP-2015-000049 and HP-2020-000034, Patents Court
[2023] EWCA Civ 73, Appeal numbers: CA-2022-000735, Court of Appeal
[2020] EWHC 1594 (Pat), Claim number: HP-2020-000011, Patents Court
[2021] EWHC 537 (Pat), Claim number: HP-2020-000012, Patents Court
[2021] EWHC 1977 (Pat), Claim number: HP-2020-000011, Patents Court
[2021] EWHC 3032 (Pat), Claim number: HP-2020-000011, Patents Court
[2022] EWHC 1284 (Pat), Claim numbers: HP-2021-000029 and HP-2022-000002, Patents Court
[2022] EWCA Civ 1638, Appeal number: CA-2021-000302, Court of Appeal
[2023] EWHC 854 (Pat), Claim number: HP-2022-000002, Patents Court
[2023] EWHC 2616 (Pat), Claim number: HP-2021-000029, Patents Court
Represented Pfizer group Warner-Lambert in enforcing its second medical use patent for blockbuster drug Lyrica® (pregabalin) as a neuropathic pain treatment against numerous generic companies in the UK and across Europe. Heralded as the IP case of the decade in the UK, it was heard in the Supreme Court in 2018 (having previously been before the Court of Appeal twice) on the most difficult issues in English patent law namely plausibility and infringement of second medical use patents.
[2015] EWHC 485 (Pat), Claim number: HC-2014-001795, Patents Court
[2015] EWCA Civ 556, Appeal numbers: A3/2015/0221 and A3/2015/0669, Court of Appeal
[2015] EWHC 2548 (Pat), Claim numbers: HP-2014-000035, HP-2014-000021, and HC-2014-001795, Patents Court
[2015] EWHC 2919 (Pat), Claim number: HP-2015-000049, Patents Court
[2015] EWHC 2924 (Pat), Claim number: HP-2015-000049, Patents Court
[2015] EWHC 3153 (Pat), Claim number: HP-2015-000049, Patents Court
[2015] EWHC 3370 (Pat), Claim numbers: HP-2014-000035, HP-2014-000021, and HC-2014-001795, Patents Court
[2016] EWCA Civ 1006, Appeal numbers: A3/2015/3415, A3/2015/3602, A3/2015/3615, and A3/2016/0017, Court of Appeal
[2016] EWHC 3317 (Pat), Claim number: HP-2015-000049, Patents Court
[2018] UKSC 56, Appeal numbers: UKSC 2016/0197, 2017/0069, and 2017/0078, Supreme Court of the United Kingdom
Conference
IAM Live: SEP Summit Global 2026 IAM Live: SEP Summit Global 2026
September 9-10, 2026
London
Conference
Life Sciences Patent Network North America Fall 2026 Life Sciences Patent Network North America Fall 2026
November 2-3, 2026
San Francisco
“Jin skilfully coordinates complex, multi-jurisdictional patent disputes. He confidently manages litigation strategies across different countries, ensuring alignment between legal teams, and adapting approaches to address jurisdiction-specific challenges. Jin has a deep understanding of his clientele and their key interests, and is remarkable in his ability to adapt to evolving situations while maintaining a focus on achieving a favourable outcome.”
Intellectual Asset Management Patent 1000
"Jin Ooi is another of the set’s seasoned litigators who comes in for high praise: ‘Jin is an incredibly bright lawyer with a sharp legal mind who works efficiently in high-pressure situations and never loses sight of the customer’s commercial needs. He immediately grasps the essence of the problem in front of him to provide excellent guidance, and is responsive around the clock.’ He performs particularly well when faced with intricate legal problems and has worked … in an incredibly complex liability and quantum trial in which they secured an overwhelmingly positive result for the company.”
Intellectual Asset Management Patent 1000
“Jin is a rising star in global patent litigation. His work inspires confidence – his approach is consistent and delivers information and advice swiftly. He is responsive, organised, understands new technologies quickly and has a deep understanding of both legal and technical aspects. Jin is an exceptionally smart patent expert. He stands out particularly for his great judgement and insight. He delivers solid strategy and is exceptional in coordinating legal matters across multiple jurisdictions.”
Intellectual Asset Management Patent 1000
“Ooi is equally strong in the pharmaceutical field but covers consumer products too - he has been credited with having ‘an attention to detail that is second-to-none’, ‘I always trust Jin to get to the heart of the technical aspects of a matter, and to do so without delay. This is the hallmark of excellent lawyers, and in Jin’s case this talent is coupled with an interest in understanding how the law varies in other jurisdictions. That is a talent which is imperative to overseeing and coordinating multi-jurisdiction patent litigation and one that clients value in Jin.'"
Intellectual Asset Management Patent 1000
"... named as 'one to watch' in UK patent litigation: an 'all-rounder', Jin 'stands out for the technical diversity of his cases, from pharmaceuticals to mobile communications to e-cigarettes - as well as his hard work and tenacity.'”
JUVE Patent
“Working across both pharmaceuticals – where he concentrates on advancements in small molecules and vaccines – and consumer goods is Jin Ooi, who can swiftly resolve even the most complex damages enquiries. He assisted on the Pfizer piece and directed patent infringement and revocation proceedings on behalf of a leading multi-category consumer goods company across 25 jurisdictions worldwide.”
Intellectual Asset Management Patent 1000
“Jin skilfully coordinates complex, multi-jurisdictional patent disputes. He confidently manages litigation strategies across different countries, ensuring alignment between legal teams, and adapting approaches to address jurisdiction-specific challenges. Jin has a deep understanding of his clientele and their key interests, and is remarkable in his ability to adapt to evolving situations while maintaining a focus on achieving a favourable outcome.”
Intellectual Asset Management Patent 1000
"Jin Ooi is another of the set’s seasoned litigators who comes in for high praise: ‘Jin is an incredibly bright lawyer with a sharp legal mind who works efficiently in high-pressure situations and never loses sight of the customer’s commercial needs. He immediately grasps the essence of the problem in front of him to provide excellent guidance, and is responsive around the clock.’ He performs particularly well when faced with intricate legal problems and has worked … in an incredibly complex liability and quantum trial in which they secured an overwhelmingly positive result for the company.”
Intellectual Asset Management Patent 1000
“Jin is a rising star in global patent litigation. His work inspires confidence – his approach is consistent and delivers information and advice swiftly. He is responsive, organised, understands new technologies quickly and has a deep understanding of both legal and technical aspects. Jin is an exceptionally smart patent expert. He stands out particularly for his great judgement and insight. He delivers solid strategy and is exceptional in coordinating legal matters across multiple jurisdictions.”
Intellectual Asset Management Patent 1000
“Ooi is equally strong in the pharmaceutical field but covers consumer products too - he has been credited with having ‘an attention to detail that is second-to-none’, ‘I always trust Jin to get to the heart of the technical aspects of a matter, and to do so without delay. This is the hallmark of excellent lawyers, and in Jin’s case this talent is coupled with an interest in understanding how the law varies in other jurisdictions. That is a talent which is imperative to overseeing and coordinating multi-jurisdiction patent litigation and one that clients value in Jin.'"
Intellectual Asset Management Patent 1000
"... named as 'one to watch' in UK patent litigation: an 'all-rounder', Jin 'stands out for the technical diversity of his cases, from pharmaceuticals to mobile communications to e-cigarettes - as well as his hard work and tenacity.'”
JUVE Patent
“Working across both pharmaceuticals – where he concentrates on advancements in small molecules and vaccines – and consumer goods is Jin Ooi, who can swiftly resolve even the most complex damages enquiries. He assisted on the Pfizer piece and directed patent infringement and revocation proceedings on behalf of a leading multi-category consumer goods company across 25 jurisdictions worldwide.”
Intellectual Asset Management Patent 1000
Commentary
Why Global IP Litigants Keep Turning to English Courts Why Global IP Litigants Keep Turning to English Courts
August 19, 2026
Managing Intellectual PropertyCommentary
UK Patent Document Access Rules Raise Secrecy Concerns UK Patent Document Access Rules Raise Secrecy Concerns
August 12, 2026
Law360Award/Ranking
Finnegan’s European Practices and Attorneys Highlighted in 2026 Managing IP Rankings Finnegan’s European Practices and Attorneys Highlighted in 2026 Managing IP Rankings
June 25, 2026
Managing Intellectual PropertyAward/Ranking
Six Finnegan Partners Recognized in the 2026 Lawdragon 500 Leading Global IP Lawyers Six Finnegan Partners Recognized in the 2026 Lawdragon 500 Leading Global IP Lawyers
June 22, 2026
The Lawdragon 500: Leading Global IP LawyersCommentary
Finnegan Taps Partner from Kirkland to Boost IP Team Finnegan Taps Partner from Kirkland to Boost IP Team
June 12, 2026
Law360Media Mention
Finnegan Hires Kirkland & Ellis Litigator for London Office Finnegan Hires Kirkland & Ellis Litigator for London Office
June 8, 2026
JUVE PatentDue to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.